



Investor Opportunity

The Developer And Manufacturer of

AQUAPRIN

THE "NEW" GOLD STANDARD FOR PAIN RELIEF

THE ULTIMATE OVER THE COUNTER PAIN RELIEVER

Espicom Business Intelligence, a market research company estimates the global pain-management market at \$46.4 billion at the close of 2011. The U.S. market accounts for 48% of that. Another market analyst, Global Industry Analysts (GIA), one year ago predicted the global pain-management market would reach \$60 billion by 2015.


Aspirin has always been, and is still considered the **"GOLD STANDARD"** of over the counter pain relievers. It is a superior non-steroidal, anti-inflammatory, pain reliever, anticoagulant, fever reducer, and anti-heart attack and stroke preventative medication. **Aspirin**, in tablet and powder forms, including Goody's powders, is acidic, non-soluble in water, and only about 40 to 45% of the drug ever gets into the blood stream. Because of these forms, it is slow to be effective, taking up to 20 to 30 minutes to reach therapeutic levels and causes side effects such as stomach bleeding and gastric upset. In millions of patients this causes severe gastric distress and sometimes even hemorrhage due to direct contact between un-dissolved aspirin particles and the stomach lining. Indeed, it is precisely these gastro-toxic, ulcerogenic adverse-reactions that prevent many patients from taking full advantage of aspirin's many benefits. The scientists at **ASPIR-TEK** have been working for over 20 years to convert common aspirin into a much more effective and safer form. What has been achieved is the most significant breakthrough in the pain reliever field in many decades and its formulation and production methods are protected by a recently granted US patent, #8,580,853.

ASPIR-TEK has improved the performance of aspirin, taking it to the highest level of safety, speed of absorption, and therapeutic performance, outperforming all currently available over the counter pain medications.


AQUAPRIN, It's Chemical characteristics A water solubilized, potassium based derivative of aspirin. (Potassium Acetylsalicylate). A single dose is: 650 mg aspirin, 300 mg of potassium.

AQUAPRIN, It's physical characteristics A free flowing crystal form packaged in 1"x2.5" foil packet, blister cards, and the "Instaprin" device, which also contains the water for dissolving the crystals. When added to 1.5 oz or more of water, the crystals totally dissolve in less than 15 seconds into a clear, effervescent tasty drink. There is no undissolved grit or residue.

AQUAPRIN, In the dissolved liquid form, virtually eliminates most of the irritation to the GI-tract. It is also the most effective and efficient method of delivering salicylates into the blood stream, achieving almost peak blood plasma levels in 5 to 7 minutes. Moreover, it contains therapeutically active levels of potassium, which acts as an antacid, neutralizing stomach acid. Potassium also lowers blood pressure and helps to dilate blood vessels allowing for better blood circulation. It is unquestionably, the safest, most effective, and fastest acting form of aspirin, and as a matter of fact, faster acting and safer, and therapeutically more effective than any other over the counter pain reliever worldwide



This randomized, double blind, crossover study in 30 volunteers involved visual inspection by gastroscopy at various time intervals after drug administration. Data shown drawn from a study by: (Jaiswal et al IUPHAR 9th International Congress of Pharmacology, 1984) Study done using "Disprin" brand soluble aspirin.



The company has manufactured and distributed over 2000 samples to outside volunteers, (under our control and supervision), who suffer from migraine and normal headaches. This includes people who have stated that they cannot tolerate aspirin. The results have been most gratifying. When the company receives adequate funding, outside third party testing facilities will be contracted to do (Claim Clinicals), to substantiate the initial results and be able to use these results in advertising. Most of the volunteers have reported superior results over prescription pain relievers and migraine medications.

Here are those results.

<u>Characteristics</u>	<u>Aspirin Tablets & Powders</u>	<u>AQUAPRIN (Potassium Acetylsalicylate)</u>
% Absorbed into the Bloodstream	40-45%	100%
Time to Therapeutic Blood Levels	20 Minutes	2 Minutes
Time to Peak blood levels	45-60 Minutes	7-10 Minutes
% In Blood Stream After 5 Minutes	Less than 5%	70-80%
Time to Start Working on Pain	20-30 Minutes	2 Minutes
Efficacy of Pain Relief	Normal	Significantly Higher
Duration of Pain Relief	3-4 Hours	5-6 Hours
Time to Relieve Headaches	25-40 Minutes	5 to 10 Minutes
Headache Relief Effectiveness	Not Tested	More that 90% in 10 min.
Effectiveness in relieving Migraine	Low	High (Proven in Studies)
Gastric Irritation	20-25% of Patients	1-2% of Patients
Gastric Damage Score	2.0	.15 (92% Less)
Effect on Gastric Mucosa	Acid	Antacid (soothing)
Dosing Method	2 or more Tablets + Glass of Water	1.5 or more oz. Drink

ASPIR-TEK's mission is to be a highly profitable leader in the OTC and prescription pain management field, and to capture a lucrative segment of the Analgesic, Arthritic, Osteoporosis, cardio protective, and migraine market. **AQUAPRIN**, and other line extension products such as **AQUAPRIN "Cough & Cold"**, **"Migraine Relief"**, and **"Menstrual"**, will have significant competitive and efficacious advantages over all other analgesics and OTC pain relievers.

ASPIR-TEK is engaged in the validation, the up fitting of a manufacturing facility, and continuous product improvement of **AQUAPRIN**, whose formulation and manufacture depend mainly upon proprietary trade secret skill and "know-how." The main formulation and manufacturing process technology patent for the product has been granted. Patent No. 8,580,853 was granted in November 2013, which protects the formulation and manufacturing process. The product is protected for at least 17 years. Additional patents are being applied for.

ASPIR-TEK has also developed the following additional products.

AQUAPRIN "Daily Regimen" Used daily for the prevention of Heart Attack & Strokes.

AQUAPRIN "Children & Teenagers". Low dose for Children & Teenagers.

AQUAPRIN "Quik-Prin" A tablet form of **AQUAPRIN** that melts in the mouth. This product is in the development stage.

AQUAPRIN "Insta-Prin" For Emergency EMS Heart Attack, Stroke Treatment, and Migraines. This is a device that holds the **AQUAPRIN** crystals and the water to react with, and for delivery into the mouth. If approved by the FDA, it can be injected directly into the blood stream.

AQUAPRIN "Oral Patch" For absorption of **AQUAPRIN** salicylates through the skin.

ASPIR-TEK is currently negotiating the purchase of our former pharmaceutical manufacturing facility in Wilson, NC, a 120,000 square ft. facility, which has much of the infrastructure already in place for R&D, manufacturing, and laboratory testing. This facility will meet current and future market demand and a substantially larger workforce. With proper funding of approximately \$7 million, the Company will be able to create roughly 150-200 jobs directly and 200-300 indirectly in the local community. The funding will accomplish the following:


1. Complete expanded construction of R&D laboratory, Pilot, and production facilities.
2. Provide laboratory, pilot, and automated production equipment.
3. Scale up to production capacity.
4. Validate processes & equipment.
5. Perform 90 day stabilities to get 2 year dating.

7. Expand laboratory area to be able to develop follow on products and line extensions.
8. Establish the manufacture, marketing, and sale of **AQUAPRIN**.
9. Thoroughly engage its professional marketing team to get **AQUAPRIN** on to drugstore shelves, hospitals, nursing homes, and into the prescription drug markets and make licensing and distribution agreements as soon as possible.
10. Continue to develop advanced formulations, improvements and line extensions
11. Complete development of the Insta-Prin Emergency administration technology.
13. Conduct "Claim" clinical trials to make specific claims for the product.
14. License distribution for European and Asian markets.

Since existing aspirin products, even with their painful side effects, currently hold a 12% market share of non-prescription analgesic usage, a 20% penetration by this highly improved product into this aspirin segment would yield sales of more than \$100-million annually.

Time is of the essence to get **AQUAPRIN commercialized and to market.**

ASPIR-TEK is looking to the sophisticated investor for the additional capital necessary to get **AQUAPRIN** to commercial reality and success. This product, with the necessary capital, can achieve over one hundred million dollars in sales annually.



A full business plan and power point presentation are available on request.

Aspir-Tek, Inc.
 3109 lakePointe Trail
 Rocky Mount, NC 27804
 Att. Howard Phykitt
 Main: 919 794 7000
 Direct Line: 919 794 7001
 Fax: 919 794 7003
 Cell: 919 633 7000

web address: www.aspir-tek.com www.aquaprin.com